Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Borraginol A is a Category 2 over-the-counter (OTC) combination medication developed by Amato Pharmaceutical Products for the relief of symptoms associated with hemorrhoids and anal fissures, including pain, bleeding, swelling, and itching. It is formulated with four active ingredients: prednisolone acetate (a mild corticosteroid that suppresses inflammation, bleeding, and swelling), lidocaine (a local anesthetic that relieves pain and itching), allantoin (which promotes wound healing and tissue repair), and tocopheryl acetate (vitamin E acetate, which improves peripheral blood circulation and relieves congestion). Borraginol A is available in multiple rectal formulations, including suppositories, ointments, and prefilled disposable applicators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Borraginol A.